VALBIOTIS SA: Valbiotis announces the signing of an exclusive distribution agreement in Qatar, a new milestone in the brand’s expansion in the Middle East

Valbiotis announces the signing of an exclusive distribution agreement in Qatar, a new milestone
in the brand’s expansion in the Middle East

• Exclusive distribution agreement signed with Al Danah Medical Company, a leading player in the healthcare and nutrition sector in Qatar.
• Launch of 4 products on the Qatari market:
  ValbiotisPRO® (ValbiotisPRO® Cholesterol, ValbiotisPRO® Metabolic Health, ValbiotisPRO® Cardio-Circulation et Steadrive®, formerly Totum 448) to begin with.
• First revenues expected as early as 2027. 

La Rochelle, June 8, 2026 (7:45 a.m CEST) – Valbiotis (FR0013254851 – ALVAL, PEA / PME eligible), a French laboratory specializing in the development and distribution of scientifically tested nutritional solutions designed to prevent cardiometabolic imbalances, announces the signing of an exclusive distribution agreement with Al Danah Medical Company, a leader in the marketing and distribution of health and nutrition products in Qatar.

Founded in 1990, Al Danah Medical Company has established itself as one of the leading distributors in Qatar’s healthcare sector, with a broad portfolio of both prescription and OTC pharmaceutical products, and nutritional solutions. The company also markets cosmetics and medical equipment.

Under the terms of this agreement, Al Danah Medical will be responsible for the registration, import, distribution and promotion of Valbiotis products to healthcare professionals throughout Qatar: pharmacists, general practitioners, specialists, and hospitals.

With deep local market insight, strong relationships across the healthcare and pharmacy sectors, and proven regulatory expertise, Al Danah Medical is well equipped to drive the successful launch and growth of the brand in the country.

Valbiotis products will be marketed primarily through pharmacies and promoted through a strategy centered on the robust scientific evidence supporting their efficacy. This approach aims to establish Valbiotis solutions as trusted benchmarks in the management of cardiometabolic health and everyday wellbeing.

Qatar presents a compelling opportunity for the ValbiotisPRO® range, given the high prevalence of cardiometabolic risk factors across the population, particularly overweight and obesity, elevated cholesterol levels, and type 2 diabetes.

Commercialization is expected to begin once the required local regulatory and health authority approvals have been obtained. This agreement is structured under a capital-light business model for Valbiotis, includes annual volume commitments, and requires no direct commercial investment from the Company.

Sébastien Peltier, CEO and Co-Founder of Valbiotis states: “The signing of this agreement in Qatar is fully aligned with our international expansion strategy. Following the partnerships recently secured across Asia and the Middle East, we are continuing to roll out the Valbiotis brand in high-potential markets. Qatar represents a particularly attractive opportunity due to the rapid development of its healthcare sector and the growing need for preventive solutions addressing cardiometabolic health challenges. We are confident that Al Danah Medical’s expertise and strong local presence will be key drivers of this partnership’s success.” 

Dr. Mohamed Afifi adds: “We are delighted to be partnering with Valbiotis to bring innovative, scientifically validated solutions to Qatari consumers and healthcare professionals alike. These products will help address the growing need for preventive healthcare.”

This agreement further strengthens Valbiotis’ presence in the Middle East, following the partnership signed in January with Mena Nutrition for distribution in Saudi Arabia, Lebanon and Iraq. It is fully in line with the Company’s international expansion strategy, which is also currently being rolled out across Asia. Valbiotis continues to pursue its ambition of expanding its international presence by leveraging its scientific expertise and unique portfolio of preventive healthcare solutions.

About Valbiotis

Valbiotis is a French laboratory specializing in the development and distribution of scientifically validated first-line nutritional solutions designed to prevent cardiometabolic imbalances. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, Valbiotis develops high-quality formulations based on patented active ingredients validated by rigorous clinical studies, designed to provide long-term support for cardiometabolic health and address associated functional issues such as sleep, fatigue, mood management, immunity and vitality. Created at the beginning of 2014 in La Rochelle, France, Valbiotis has forged numerous partnerships with leading academic centers.

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label.  Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information on Valbiotis®, please visit: www.valbiotis.com

Contacts

Corporate Communication / Valbiotis

Caroline Lamberti

+ 33 6 77 82 56 88

caroline.lamberti@valbiotis.com

Financial communication / Seitosei.Actifin 

Marianne Py

+33 6 85 52 76 93

marianne.py@seitosei-actifin.com

Press Relations / LJ Com by JIN

Valentine Martin

+33 6 32 29 43 82
v.martin@ljcom.net

Name: Valbiotis
ISIN Code: FR0013254851

Ticker Symbol: ALVAL

EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the Valbiotis Universal Registration Document, filed with the French Financial Markets Regulator (AMF) on April 26, 2023, under number D.23-0347, as well as in its Amendment filed with the AMF on December 11, 2023, under number D.23-0347.A01. These documents are available on the Company's website (www.valbiotis.com).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.